Sept. 10 - Altor BioScience has secured exclusive worldwide rights to develop Massachusetts General Hospital’s T-cell receptor technology for use in the treatment of HIV and hepatitis C. New medicines are needed as AIDS and HIV patients continue to develop resistance to existing anti-retroviral drugs, Altor said. Boston Business Journal